Sep. 1 at 4:38 PM
$CRBU Not too ancient data "Last month, Caribou presented new data from a phase 1 trial of vispa-cel, a single-dose, patient-ready option, showing its donor-derived treatment produced a progression-free survival rate of 17.1 months in B-cell non-Hodgkin lymphoma. By comparison, separate trials for Breyanzi and Yescarta showed progression-free survival rates of 14.8 months and 14.9 months, respectively. Caribous notched that win even though its patient population was sicker than those in trials for the other drugs, according to the biotech's CEO and founder, Rachel Haurwitz.
Overall, some 82% of patients responded to the treatment and 67% saw a complete response with a safety profile that was largely similar to Breyanzi, she said. "
